Purpose Bio is developing proprietary novel therapeutics to treat metabolic syndrome diseases. 

Our first focused indications are NAFLD/NASH: Non-Alcoholic Fatty Liver Disease and Hyperlipidemia. 

100 Million adults in the U.S suffer from NAFLD and 60 Million adults in the U.S with Hyperlipidemia, are either intolerant or refuse taking traditional lipid lowering medicines, due to adverse side effects.